Market Overview

Exelixis Announces Full Patient Enrollment for COMET-1 Phase 3 Trial


Exelixis, Inc. (NASDAQ: EXEL) today announced that the enrollment target
of 960 patients has been reached for COMET-1, the company's phase 3
pivotal trial of cabozantinib in patients with metastatic
castration-resistant prostate cancer (mCRPC). The primary endpoint of
COMET-1 is overall survival, and Exelixis continues to expect top-line
data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014.

COMET-1 is a randomized, double-blind, placebo-controlled trial designed
to enroll 960 patients with mCRPC who have previously been treated with
docetaxel, abiraterone acetate and/or enzalutamide. All patients in the
trial have bone metastases and there is no limit to the number or type
of prior treatments. Patients are randomized 2:1 to receive cabozantinib

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (EXEL)

View Comments and Join the Discussion!